# Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

Source: https://onco.cc/trials/nct06118086/  
OnCo record `nct06118086` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of REM-422 in salivary gland cancers, run by Remix Therapeutics, now recruiting.

## Summary

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma is a phase 1/2 interventional study registered as NCT06118086 by Remix Therapeutics, with 125 participants planned, started 2023-12-20 and due to reach its primary completion in 2027-09-30. Interventions recorded: REM-422.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06118086
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
- Sponsor: Remix Therapeutics
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT06118086: https://clinicaltrials.gov/study/NCT06118086

## Connected records

- cancers: [Salivary gland cancers](https://onco.cc/cancers/salivary-gland/)
- drugs: [REM-422](https://onco.cc/drugs/rem-422/)

---
JSON: https://onco.cc/api/v1/entities/nct06118086.json